DBV Technologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
June 05 2024 - 4:30PM
DBV Technologies to Participate in the Goldman Sachs 45th Annual
Global Healthcare Conference
Châtillon, France, June 5, 2024
DBV Technologies to
Participate in the Goldman Sachs
45th Annual Global Healthcare
Conference
DBV Technologies (Euronext: DBV – ISIN:
FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage
biopharmaceutical company focused on treatment options for food
allergies and other immunologic conditions with significant unmet
medical need, today announced that Daniel Tassé, Chief Executive
Officer, will participate in a fireside chat at the 45th Annual
Goldman Sachs Global Healthcare Conference on Monday, June 10th, at
8:00 am EDT, as well as in one-on-one investor meetings.
A live webcast of the presentation can be accessed
here, and will also be available on the Events section of Company’s
Investors website:
https://dbv-technologies.com/investor-overview/events/
A replay will also be available on DBV
Technologies’ website for 90 days after the event.
About DBV TechnologiesDBV
Technologies is a clinical-stage biopharmaceutical company
developing treatment options for food allergies and other
immunologic conditions with significant unmet medical need. DBV is
currently focused on investigating the use of its proprietary
technology platform, Viaskin™, to address food allergies, which are
caused by a hypersensitive immune reaction and characterized by a
range of symptoms varying in severity from mild to life-threatening
anaphylaxis. Millions of people live with food allergies, including
young children. Through epicutaneous immunotherapy (EPIT™), the
Viaskin platform is designed to introduce microgram amounts of a
biologically active compound to the immune system through intact
skin. EPIT is a new class of non-invasive treatment that seeks to
modify an individual’s underlying allergy by re-educating the
immune system to become desensitized to allergen by leveraging the
skin’s immune tolerizing properties. DBV is committed to
transforming the care of food allergic people. The Company’s food
allergy programs include ongoing clinical trials of Viaskin Peanut
in peanut allergic toddlers (1 through 3 years of age) and children
(4 through 7 years of age).
DBV Technologies is headquartered in Châtillon,
France, with North American operations in Warren, NJ. The Company’s
ordinary shares are traded on segment B of Euronext Paris (Ticker:
DBV, ISIN code: FR0010417345) and the Company’s ADSs (each
representing one-half of one ordinary share) are traded on the
Nasdaq Stock Market (Ticker: DBVT).
For more information, please visit
www.dbv-technologies.com and engage with us on X (formerly Twitter)
and LinkedIn.
Viaskin and EPIT are trademarks of DBV
Technologies.
Investor Contact Katie
MatthewsDBV Technologieskatie.matthews@dbv-technologies.com
Media ContactAngela MarcucciDBV
Technologiesangela.marcucci@dbv-technologies.com
DBV Technologies (EU:DBV)
Historical Stock Chart
From Jul 2024 to Aug 2024
DBV Technologies (EU:DBV)
Historical Stock Chart
From Aug 2023 to Aug 2024